# Vertex Total Asset

VRTX | Stock | ## USD 321.32 3.74 1.18% |

Vertex Pharmaceuticals fundamentals help investors to digest information that contributes to Vertex Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Vertex Stock. The fundamental analysis module provides a way to measure Vertex Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Vertex Pharmaceuticals stock.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Vertex | Total Asset |

## Vertex Total Asset Analysis

Vertex Pharmaceuticals' Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value. 2019 | 2020 | 2021 | 2022 (projected) | |

Receivables | 633.52 M | 885.35 M | 1.14 B | 1.23 B |

Inventories | 167.5 M | 280.78 M | 353.1 M | 380.98 M |

Total Asset | = | Tangible Assets | + | Intangible Assets |

## Current Vertex Pharmaceuticals Total Asset | 13.43 B |

Most of Vertex Pharmaceuticals' fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Vertex Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

## Vertex Total Asset Driver Correlations

Understanding the fundamental principles of building solid financial models for Vertex Pharmaceuticals is extremely important. It helps to project a fair market value of Ford stock properly, considering its historical fundamentals such as Total Asset. Since Vertex Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Vertex Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Vertex Pharmaceuticals' interrelated accounts and indicators.

## Vertex Total Asset Historical Pattern

Today, most investors in Vertex Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Vertex Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Vertex Pharmaceuticals total asset as a starting point in their analysis.

Vertex Pharmaceuticals Total Asset |

Share

Timeline |

Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.

Compare to competition |

## Vertex Total Assets

## Total Assets | ## 14.49 Billion |

Based on the latest financial disclosure, Vertex Pharmaceuticals has a Total Asset of 13.43

**B**. This is 78.63% higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The total asset for all United States stocks is 54.41% higher than that of the company.## Vertex Total Asset Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vertex Pharmaceuticals' direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Vertex Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Vertex Pharmaceuticals by comparing valuation metrics of similar companies.Vertex Pharmaceuticals is currently under evaluation in total asset category among related companies.

## Vertex Pharmaceuticals Current Valuation Drivers

We derive many important indicators used in calculating different scores of Vertex Pharmaceuticals from analyzing Vertex Pharmaceuticals' financial statements. These drivers represent accounts that assess Vertex Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Vertex Pharmaceuticals' important valuation drivers and their relationship over time.

2017 | 2018 | 2019 | 2020 | 2021 | 2022 (projected) | ||

Net Income Per Employee | 114.56 K | 838.76 K | 392.27 K | 795.36 K | 600.54 K | 647.95 K | |

Revenue Per Employee | 1.08 M | 1.22 M | 1.39 M | 1.82 M | 1.94 M | 2.1 M | |

Earnings Before Interest Taxes and Depreciation Amortization EBITDA | 103.26 M | 706.76 M | 1.5 B | 3.26 B | 2.91 B | 3.14 B |

## Vertex Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Vertex Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Vertex Pharmaceuticals' managers, analysts, and investors.Environment Score | Governance Score | Social Score |

## Vertex Fundamentals

Return On Equity | 0.29 % | |||

Return On Asset | 0.14 % | |||

Profit Margin | 0.38 % | |||

Operating Margin | 0.37 % | |||

Current Valuation | 73.55 B | |||

Shares Outstanding | 256.69 M | |||

Shares Owned by Insiders | 0.18 % | |||

Shares Owned by Institutions | 95.49 % | |||

Number of Shares Shorted | 3.03 M | |||

Price to Earning | 24.57 X | |||

Price to Book | 6.33 X | |||

Price to Sales | 9.37 X | |||

Revenue | 7.57 B | |||

Gross Profit | 3.62 B | |||

EBITDA | 2.92 B | |||

Net Income | 2.34 B | |||

Cash and Equivalents | 9.77 B | |||

Cash per Share | 38.06 X | |||

Total Debt | 824.6 M | |||

Debt to Equity | 0.06 % | |||

Current Ratio | 4.70 X | |||

Book Value Per Share | 50.77 X | |||

Cash Flow from Operations | 2.64 B | |||

Short Ratio | 1.88 X | |||

Earnings Per Share | 12.43 X | |||

Price to Earnings To Growth | 0.42 X | |||

Target Price | 323.94 | |||

Number of Employees | 3.9 K | |||

Beta | 0.43 | |||

Market Capitalization | 81.52 B | |||

Total Asset | 13.43 B | |||

Retained Earnings | (6.34 B) | |||

Working Capital | 900.8 M | |||

Current Asset | 1.41 B | |||

Current Liabilities | 506.35 M | |||

Z Score | 62.3 | |||

Net Asset | 13.43 B |

## About Vertex Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Vertex Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vertex Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vertex Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.Last Reported | Projected for 2022 | ||

Total Assets | 13.4 B | 14.5 B | |

Total Assets Per Share | 52.78 | 56.95 | |

Net Current Assets as percentage of Total Assets | 55.23 | 47.94 | |

Average Assets | 2.4 B | 2.6 B | |

Tangible Asset Value | 2.3 B | 2.5 B |

## Be your own money manager

Our tools can tell you how much better you can do entering a position in Vertex Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.## Did you try this?

### Run Equity Analysis Now

## Equity AnalysisResearch over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |

All Next | Launch Module |

## Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Also, please take a look at Vertex Pharmaceuticals Piotroski F Score and Vertex Pharmaceuticals Altman Z Score analysis. You can also try Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.

## Complementary Tools for analysis

When running Vertex Pharmaceuticals price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Earnings CallsCheck upcoming earnings announcements updated hourly across public exchanges | Go | |

Headlines TimelineStay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | Go | |

Fundamentals ComparisonCompare fundamentals across multiple equities to find investing opportunities | Go | |

Equity SearchSearch for actively traded equities including funds and ETFs from over 30 global markets | Go | |

Global Markets MapGet a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | Go | |

Portfolio SuggestionGet suggestions outside of your existing asset allocation including your own model portfolios | Go | |

Balance Of PowerCheck stock momentum by analyzing Balance Of Power indicator and other technical ratios | Go | |

Portfolio CenterAll portfolio management and optimization tools to improve performance of your portfolios | Go | |

CEO DirectoryScreen CEOs from public companies around the world | Go |

Is Vertex Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vertex Pharmaceuticals. If investors know Vertex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vertex Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth YOY 0.095 | Market Capitalization 81.5 B | Quarterly Revenue Growth YOY 0.177 | Return On Assets 0.1368 | Return On Equity 0.2902 |

The market value of Vertex Pharmaceuticals is measured differently than its book value, which is the value of Vertex that is recorded on the company's balance sheet. Investors also form their own opinion of Vertex Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Vertex Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vertex Pharmaceuticals' market value can be influenced by many factors that don't directly affect Vertex Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Vertex Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Vertex Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vertex Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.